主な研究実績
2020年
◆発表論文(英文)
1. Pharmacological Actions of Indoxyl Sulfate and AST-120 That Should Be Recognized for the Strategic Treatment of Patients with Chronic Kidney Disease.
Nagata D, Yoshizawa H.
Int J Nephrol Renovasc Dis. 2020 Dec 4;13:359-365. doi: 10.2147/IJNRD.S287237. eCollection 2020.
2. Protection of Dialysis Staff From COVID-19 Infection: Setting Up and Impact of Extended Blood Lines During Dialysis.
Matsuoka R, Masuda T, Akiyama Y, Muto T, Miyamoto Y, Imai T, Kamiyama T, Yokoyama M, Iwamoto S, Sugie S, Ono K, Nagayama I, Kohara-Miura M, Komada T, Suzuki M, Maeshima A, Akimoto T, Saito O, Nagata D.
ASAIO J. 2020 Nov/Dec;66(10):1073-1075. doi: 10.1097/MAT.0000000000001240.
d
3. Acute Interstitial Nephritis and Acute Tubular Injury Due to a Transdermal Loxoprofen Patch.
Shinzato T, Ohara K, Kaminaga H, Sugase T, Masuda T, Nagata D, Saki K, Kinoshita Y, Kubo T, Shimizu T, Nanmoku K, Yagisawa T.
Intern Med. 2020;59(21):2733-2736.
k
4. A role for the tubular Na+-H+-exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin.
Onishi A, Fu Y, Patel R, Darshi M, Crespo-Masip M, Huang W, Song P, Freeman B, Kim YC, Soleimani M, Sharma K, Thomson SC, Vallon V.
Am J Physiol Renal Physiol. 2020 Sep 7. doi: 10.1152/ajprenal.00264.2020. Online ahead of print.
5. Practical Strategy for Treating Chronic Kidney Disease (CKD)-Associated with Hypertension.
Nagata D, Hishida E, Masuda T.
Int J Nephrol Renovasc Dis. 2020 Jul 7;13:171-178. doi: 10.2147/IJNRD.S259931. eCollection 2020.
6. Recent advances in the management of secondary hypertension: chronic kidney disease.
Masuda T, Nagata D.
Hypertens Res. 2020 Sep;43(9):869-875. doi: 10.1038/s41440-020-0491-4. Epub 2020 Jun 17.
7. The extracellular volume status predicts body fluid response to SGLT2 inhibitor dapagliflozin in diabetic kidney disease.
Ohara K, Masuda T, Morinari M, Okada M, Miki A, Nakagawa S, Murakami T, Oka K, Asakura M, Miyazawa Y, Maeshima A, Akimoto T, Saito O, Nagata D.
Diabetol Metab Syndr. 2020 May 1;12:37. doi: 10.1186/s13098-020-00545-z. eCollection 2020.
1
8. Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume.
Masuda T, Muto S, Fukuda K, Watanabe M, Ohara K, Koepsell H, Vallon V, Nagata D.
Physiol Rep. 2020 Jan;8(2):e14360. doi: 10.14814/phy2.14360.
◆発表論文(和文)
＜原著＞
1. 病態評価に苦慮した新規縦隔内病変と自家移植片を有する二次性副甲状腺機能亢進症の 1 例 New
岡健太郎, 武田真一, 大原健, 村上琢哉, 菅生太朗, 久保太郎, 清水俊洋, 八木澤隆, 齋藤修, 長田太助
腎と透析. 89 (6), 1040-1043
2. 妊娠を契機にループ利尿薬と下剤の大量服用を中止し，急激な体重増加と浮腫を認めた一例 New
岡健太郎，小林高久，村上琢哉，朝倉真希，菅生太朗，増田貴博，前嶋明人，秋元哲，齋藤修，長田太助
臨床体液 47, 12-16
＜その他＞
1. SGLT2阻害薬の効果と服用方法 New
増田貴博
ドクターサロン64巻2月号 (1.2020)
